Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)
Twitter
Tags: Biotechnology
Stocks: GLPG, INSY

Our "War on Pain" Biotech Put You Up by Double Digits in Just Two Weeks

And FDA approval means a lot more gains are likely ahead of us...

By William Patalon III, Executive Editor, Money Morning • May 30, 2017

View Comments

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

William Patalon IIIWilliam Patalon III

Editor's Note: On May 15, Bill shared a very special recommendation with us - a biotech with a possible "blockbuster" cannabis-derived drug - because he wanted everyone to see just how potentially profitable (and diverse) the legal marijuana sector can be for regular investors. He's got great news for us this morning: a bumper crop of big, fast gains. Here's Bill...

Insys Therapeutics Inc. (Nasdaq: INSY) - our "War on Pain" biotech play - has given us a profit of more than 10.7% since we recommended the stock a little less than two weeks ago.

I hope you like profits, because that's just for starters.

The U.S. Food and Drug Administration (FDA) last week approved the final "product label" for the company's new synthetic marijuana drug - which means Insys can bring this new therapy to market in August.

Investors who specialize in drug stocks are always trying to pull profits from trades based on the three-step FDA "phalanx" that up-and-coming biotechs must navigate to finally get a new drug to market.

But if you really want to cash in, commercialization is the "triggering event" that can make that happen.

And that's exactly where Insys is right now.

Sign up for SMS so you never miss special events, exclusive offers, and weekly bonus trades.
Let me give you a little bit of context here - before I explain exactly what's going to happen next...

These Companies Can Bring Huge Investor Profits

The drug-development process is one I know well. The decades I spent as a business journalist included long stints on the biotech beat.

And during that time, I learned - firsthand - why it can take 10 years and a billion dollars to bring a drug candidate out of the lab, take it through the FDA regulatory gauntlet, and finally end up with a drug that can generate real revenue and profits.

I've employed that expertise to a very profitable advantage for my paid-up Private Briefing subscribers.

I understand the biotech sector, I understand the "right" stocks to pick, and I understand how big new trends can trigger some of the heftiest windfalls you see.

The very first stock that I recommended on the very first day of Private Briefing's Ā life back in August 2011 was a development-stage drug firm called Galapagos NV (Nasdaq ADR: GLPG). From the "Buy" price of $8.60 a share, Galapagos soared to a recent peak of $94.88.

Best of all: I re-recommended it over and over on the way up, meaning thousands of subscribers had multiple chances to grab hefty slices of this 1,003% peak gain.

Back in 2012, I studied the big pharma sector - and could see that the top players were facing a "patent cliff" on their blockbuster drugs. But I also saw that those firms were stuffed with cash from those big-profit drugs - and predicted those firms would embark on shopping sprees to replace those going-off-patent drugs.

I predicted a "Biotech Buyout Boom" - and identified three stocks that could be takeover targets. All three stocks I recommended zoomed, and one - a cancer pioneer - brought my readers an 818% profit.

So I understand the biotech sector, I understand the "right" stocks to pick, and I understand how big new trends can trigger some of the heftiest windfalls you see.

And two of the biggest new trends offer us some of the biggest potential gains with Insys. Those trends...

  • The "War on Pain" - where doctors, currently on the front lines of the so-called "Opioid Crisis" of overdose deaths, are trying to find non-opioid drugs that can solve chronic pain.
  • The "Legalization of Medical Marijuana," where doctors, researchers, and our elected leaders, recognizing the broad treatment potential of cannabinoid-based therapies - are ramping up research even as they drop legal barriers for marijuana-based drugs.

Here's what I mean...

Join the conversation. Click here to jump to comments…

William Patalon IIIWilliam Patalon III

About the Author

Browse William's articles | View William's research services

Before he moved into the investment-research business in 2005, William (Bill) Patalon III spent 22 years as an award-winning financial reporter, columnist, and editor. Today he is the Executive Editor and Senior Research Analyst for Money Morning at Money Map Press.

… Read full bio

Login
guest
guest
8 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Gary Martin
Gary Martin
6 years ago

Sounds like a license to steal. I love it I want alot of it

0
Reply
G13Man
G13Man
6 years ago

but will this really be that big with all the new outlets for the real thing ?

0
Reply
ELLIOTT
ELLIOTT
6 years ago

Naturally Splendid Enterprises, B.C. Canada
Hey, Mr. Patalon,
Am wondering if you have heard about these folks in Canada signing
an agreement to sell their tablets of hemp oil in Japan? Sounds like a sleeper, or maybe not; but they are looking at Korea also. I do not understand the value of these products, as the Japanese are very astute buyers on quality, healthful benefits. Would like to know your thoughts!

0
Reply
Janete U Bequeaith
Janete U Bequeaith
6 years ago

I was reading the article about the doctors who were just convicted of running a "pill mill" and were given kickbacks by Insys. Still a good company to be involved in??

0
Reply
Denys
Denys
5 years ago

I guess everything else goes out the window when it comes to making money. Let us travel back in time for a moment and really take in the hypocrisy of this large pharmaceutical company (which also manufactures the deadly painkiller Subsys fentanyl) which has dramatically increased opioid addiction and overdoses in the U.S. In September, the anti-legalization initiative, Arizonans for Responsible Drug Policy, received a donation of $500,000 from Insys and was one of the largest single contributions to any anti-legalization campaign. In February 2016, a former sales rep for Insys pleaded guilty to fraud charges due to a kickback scheme involving Subsys fentanyl sales. Then, on August 2016, two former employees pleaded not guilty after they were arrested due to accusations for partaking in a similar kickback scheme for the drug. If you’re unaware, a kickback scheme is a form of negotiated bribery where commission is paid to the bribe-taker in exchange for services, and in this instance, highly addictive opioid sales. The motivations of the DEA are thrown into question when they back a drug manufactured by a morally controversial pharmaceutical company. When marijuana is grown in its natural plant form, it is an illegal and ā€œhighly addictiveā€ drug with no accepted medical value. But when a pharmaceutical company develops a synthetic version that would likely cost patients more, the DEA is much more open minded.

0
Reply
steve
steve
5 years ago
Reply to  Denys

TouchƩ !!!!!!!!

0
Reply
David Dickerson
David Dickerson
5 years ago

on time news good all ther time thank you money morning.

0
Reply
Thanh Quang la
Thanh Quang la
5 years ago

It's a good new for old man like me.I often finding the better one .Thanh

0
Reply


Latest News

May 30, 2023 • By Chris Johnson

A.I., Oil, and Interest Rates - Oh My

May 30, 2023 • By Shah Gilani

earnings
The Best Way to Play the Tech Stock Boom

May 30, 2023 • By Garrett Baldwin

Momentum Is Negative - Here Are Three Wealth Strategies to Employ Right Away
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Flashpoint Trader Darknet Hyper Momentum Trader Alpha Accelerators Weekly Profit Cycles Brutus Alerts Resource Traders Alliance

Ā© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information

wpDiscuz